Consensus target puts Cochlear stock at AUD 136.34

Published on 10/27/2026 at 18:47 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

FY27 profit guidance stayed at AUD 330 million to AUD 350 million on October 26, 2026. Cochlear stock costs EUR 87.48 on October 27, 2026.

Analyst target and profit guidance

A consensus target of AUD 136.34 from 16 analysts was listed on October 27, 2026.
Cochlear reaffirmed FY27 underlying net profit guidance of AUD 330 million to AUD 350 million on October 26, 2026.
Cochlear stock costs EUR 87.48 at Lang & Schwarz on October 27, 2026 at 6:42 p.m. CEST.
Professor Ian Meredith is scheduled to join the board on December 1, 2026.

Cochlear, AU000000COH5, Illustration mit AI erstellt.

On October 27, 2026, Simply Wall St listed a Cochlear consensus target of AUD 136.34 from 16 analysts, putting the figure below the latest ASX quotation. Cochlear was trading at EUR 87.48 at Lang & Schwarz on October 27, 2026 at 6:42 p.m. CEST.

Profit guidance stays intact

Cochlear reaffirmed underlying net profit guidance of AUD 330 million to AUD 350 million for fiscal year 2027 at its annual meeting on October 26, 2026. The SureStone summary said fiscal year 2026 underlying net profit was AUD 322 million on sales revenue of AUD 2.3 billion.

The companys annual meeting materials also described fiscal year 2026 sales revenue of AUD 2.3 billion, up 2 percent in constant currency, while underlying net profit was AUD 322 million. The Listcorp-hosted company announcement said the Nexa implant accounted for more than 95 percent of developed-market implant sales by June.

ASX range remains wide

The latest ASX quotation was AUD 139.82 on October 27, 2026 at 4:10 p.m. AEDT, while the 52-week range stood at AUD 88.74 to AUD 296.50. Cochlear therefore traded AUD 156.68 below its 52-week high and AUD 51.08 above its 52-week low. Its market capitalization was AUD 9.1 billion.

Valuation and board date

The current price stood above the AUD 136.34 consensus target by 2.55 percent, calculated from the ASX quotation and the target. That gap leaves the target as a clear reference point for investors weighing the recovery outlook against the weak fiscal year 2026 earnings base.

Professor Ian Meredith is scheduled to join Cochlear as an independent non-executive director on December 1, 2026. The appointment was included in the October 26 company announcement and adds medical technology experience to the board.

Stock position in context

Cochlear operates in implantable hearing solutions and sells products in more than 180 countries. The company said adult medicalization and stronger referral pathways remain central to its fiscal year 2027 plan, while the Nexa platform and fully implantable hearing research provide longer-term product drivers.

At Lang & Schwarz, Cochlear was trading at EUR 87.48 on October 27, 2026 at 6:42 p.m. CEST. The further course of trading is shown by the continuously updated real-time quote of Cochlear stock.